Precipio inc (PRPO) - News Archive

In a significant move reflecting its strategic financial approach, Precipio Inc. announced the termination of its Automated Teller Machine (ATM) management decision. This decision is aligned with the company’s commitmen...

In a notable departure from traditional equity compensation structures, Precipio Inc. has announced a strategic shift in how they incentivize senior management. In a press release dated October 8, 2024, the company reve...

As the landscape of cancer diagnostics continues to evolve, Precipio, Inc. has positioned itself at the forefront of innovative testing solutions. The company, known for its specialty diagnostics focused on hematologic...

Precipio Announces Employee Stock Option Plan Repricing: Analysis and Impact on ShareholdersOn (date), Precipio Inc. announced the repricing of their Employee Stock Option Plan, outlining the rationale behind this decis...

The highly anticipated shareholders meeting for ABC Corporation has been rescheduled to Friday, June 21 at 9 a.m. Eastern Time. This meeting promises to be a significant event for the company and its investors, as impor...

Precipio Provides Insightful Status Update on Current Business MattersNEW HAVEN, Conn., June 12, 2024 - Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, recently shared important updates with its s...

Precipio Secures a $500K Credit Facility Loan to Offset Cashflow Deficit Amid Cybersecurity AttackIn the wake of the debilitating cyberattack on Change Healthcare, Precipio, a leading healthcare diagnostics company, has...

Driven by a commitment to provide patients with precise diagnostic tools, the specialty cancer diagnostics firm Precipio, Inc. (NASDAQ: PRPO) has made a landmark announcement. Precipio recently inked a distribution agre...

In a major breakthrough, Precipio, a global diagnostics company specializing in the field of cancer diagnostics, has recently signed a distribution agreement for its innovative IV-Cell and HemeScreen technologies in Jap...

Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), recently shared its thoughts and reflections on the year 2023 while expressing its optimism and expectations for the upcoming year, 2024. This article...